Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-202 phase 2 study of enfortumab vedotin in advanced or metastatic solid tumors
jRCT2080225095Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of enfortumab vedotin and pembrolizumab in breast cancer, triple-negative breast cancer (TNBC), Pulmonary squamous cell carcinoma and 3 more (9 cohorts), sponsored by Astellas Pharma. Started Feb 2020; status: completed.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
breast cancertriple-negative breast cancer (TNBC)Pulmonary squamous cell carcinomaNon-small cell lung cancer (NS-NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080225095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225095.